Academic Journal
Bone Deleterious Effects of Different NRTIs in Treatment-naïve HIV Patients After 12 and 48 Weeks of Treatment
| العنوان: | Bone Deleterious Effects of Different NRTIs in Treatment-naïve HIV Patients After 12 and 48 Weeks of Treatment |
|---|---|
| المؤلفون: | Atencio, Patricia, Conesa-Buendía, Francisco Miguel, Cabello Ubeda, Alfonso, Lla-Mas-granda, Patricia, Pérez-Tanoira, Ramón, Prieto Pérez, Laura, Álvarez, Beatriz Álvarez, Acosta, Irene Carrillo, Arboiro-Pinel, Rosa, Díaz-Curiel, Manuel, Largo, Raquel, Herrero-Beaumont Cuenca, Gabriel, Górgolas Hernández-Mora, Miguel, Mediero, Aránzazu |
| المساهمون: | UAM. Departamento de Medicina |
| بيانات النشر: | Bentham Science Publishers B.V. |
| سنة النشر: | 2022 |
| المجموعة: | Universidad Autónoma de Madrid (UAM): Biblos-e Archivo |
| مصطلحات موضوعية: | Abacavir, Bone markers, HIV, Osteopenia, Osteoporosis, Tenofovir, Medicina |
| الوصف: | Background: Bone alterations have been observed in the course of HIV infection, char-acterized by a marked decrease in bone mineral density (BMD) and an increase in the frequency of fractures as a result of fragility. We aim to evaluate early changes in bone metabolic profile and the possible association with tenofovir and other nucleoside and nucleotide reverse transcriptase inhibi-tors (NRTIs) in treatment-naïve HIV patients. Methods: We conducted a prospective study in naïve HIV-infected adults (under 50 years), separat-ed into three groups according to NRTI therapy: tenofovir disoproxil fumarate (TDF); tenofovir alafenamide (TAF) and abacavir (ABC). BMD and epidemiological, immunological and metabolic bone parameters were evaluated. Bone markers were analyzed in plasma at baseline, 12 and 48 weeks after initiating treatment. Results: Average age of patients was 34.8 years (± 9.6). 92.4% of them with CD4 count > 200 cel/μL. At week 12 after starting treatment, both TDF [increase in PN1P (31.7%, p = 0.004), TRAP (11.1%, p = 0.003), OPN (19.3%, p = 0.045) and OC (38.6%, p = 0.001); decrease in OPG (-23.4%, p = 0.003)] and TAF [increase in 42.6% for CTX (p = 0.011), 27.3% for OC (p = 0.001) and 21% for TRAP (p = 0.008); decrease in OPG (-28.8%, p = 0.049)] presented a deep resorption profile compared to ABC, these differences in bone molecular markers, a tendency to equalize at week 48, where no significant differences were observed. Patients treated with TDF showed the greatest decrease in Z-score in both lumbar spine (LS) and femoral neck (FN) at week 48 without statistically significant differences. Conclusion: Treatment-naïve HIV patients have a high prevalence of low bone density. Treatment with TDF is associated with greater bone deterioration at 12 and 48 weeks. TAF seems to present similar early bone deterioration at 12 weeks which disappears at 48 weeks. ; This research was financially supported by The Carlos III Health Institute through the “Miguel Servet” program (CP15/00053), co-funded by The ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| Relation: | Current HIV Research; Gobierno de España. PI16/00991; Gobierno de España. PI19/00744); Current HIV Research 19.5 (2021): 434-447; 1873-4251 (online); 1570-162X (print); http://hdl.handle.net/10486/705102; 434; 447; 19 |
| DOI: | 10.2174/1570162X19666210805094434 |
| الاتاحة: | http://hdl.handle.net/10486/705102 https://doi.org/10.2174/1570162X19666210805094434 |
| Rights: | © 2021 Bentham Science Publishers ; Reconocimiento ; openAccess |
| رقم الانضمام: | edsbas.C46E1460 |
| قاعدة البيانات: | BASE |
| DOI: | 10.2174/1570162X19666210805094434 |
|---|